Laurie B. Keating
2018 - Alnylam Pharmaceuticals
In 2018, Laurie B. Keating earned a total compensation of $1.6M as Executive Vice President, Chief Legal Officer and Secretary at Alnylam Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $144,000 |
|---|---|
| Option Awards | $990,584 |
| Salary | $446,700 |
| Other | $32,734 |
| Total | $1,614,018 |
Keating received $990.6K in option awards, accounting for 61% of the total pay in 2018.
Keating also received $144K in non-equity incentive plan, $446.7K in salary and $32.7K in other compensation.
Rankings
In 2018, Laurie B. Keating's compensation ranked 6,814th out of 14,244 executives tracked by ExecPay. In other words, Keating earned more than 52.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,814 out of 14,244 | 52nd |
Division Manufacturing | 2,607 out of 5,765 | 55th |
Major group Chemicals And Allied Products | 980 out of 2,128 | 54th |
Industry group Drugs | 822 out of 1,817 | 55th |
Industry Pharmaceutical Preparations | 641 out of 1,391 | 54th |
Source: SEC filing on April 2, 2021.
Keating's colleagues
We found four more compensation records of executives who worked with Laurie B. Keating at Alnylam Pharmaceuticals in 2018.